Array Biopharma (NASDAQ: ARRY) reported Q4 EPS of ($0.17), $0.04 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $33.8 million versus the consensus estimate of $28.61 million.

Cash, Cash Equivalents and Marketable Securities as of June 30, 2017 were $235.1 million.

For earnings history and earnings-related data on Array Biopharma (ARRY) click here.